Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
10 févr. 2020 20h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.
22 janv. 2020 07h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference
13 déc. 2019 08h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
04 déc. 2019 08h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Seelos Therapeutics to Participate in Upcoming Investor Conferences in December
01 nov. 2019 10h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
Seelos Therapeutics to Participate in Upcoming Investor Conference in November
18 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
15 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos Therapeutics to Participate in Upcoming Investor Conference in September
04 sept. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer Fall...
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
23 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...